Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
Current influenza vaccines target highly variable surface glycoproteins; thus, mismatches between vaccine strains and circulating strains often diminish vaccine protection. For this reason, there is still a critical need to develop effective influenza vaccines able to protect also against the drift...
Saved in:
Main Authors: | Maria Victoria Sanchez (Author), Thomas Ebensen (Author), Kai Schulze (Author), Diego Esteban Cargnelutti (Author), Eduardo A. Scodeller (Author), Carlos A. Guzmán (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity
by: Thomas Ebensen, et al.
Published: (2023) -
BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
by: Deepender Kaushik, et al.
Published: (2020) -
Designing a bis-azide photoaffinity probe in labeling influenza nucleoprotein trimer to give an insight into the binding mode
by: Pin-Hsuan Chiu, et al.
Published: (2022) -
TLR5 Signaling in the Regulation of Intestinal Mucosal Immunity
by: Feng S, et al.
Published: (2023) -
Detection of Antibody and Antigen for Lassa Virus Nucleoprotein in Monkeys from Southern Nigeria
by: Bamidele Nyemike Ogunro, et al.
Published: (2019)